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and Nasser Hanna, MD*
Purpose: Pemetrexed is a standard treatment against recurrent
non-small cell lung cancer (NSCLC), and cetuximab has single-
agent activity against NSCLC. This study evaluates the safety and
efficacy of the combination of these agents in patients with advanced
NSCLC.
Patients and Methods: Patients with recurrent NSCLC and an
Eastern Cooperative Oncology Group performance status of 0 to 1
were entered. Patients on the phase I portion of the study received
cetuximab 400 mg/m2 intravenously (IV) on day 7 followed by
weekly doses of cetuximab at 250 mg/m2 IV with escalating doses
of pemetrexed every 3 weeks (dose levels: 500, 600, 750, 900
mg/m2) in a standard 3  3 design. Once the maximum tolerated
dose (MTD) of the combination was determined, patients were
enrolled on the phase II portion. The primary end point was to
determine the median time to disease progression (TTP) (null
hypothesis 12 weeks, alternative hypothesis 24 weeks).
Results: Thirty-six patients were enrolled (phase I: n 13, phase II:
n  23). Patient characteristics included 60.6% men, median age 64
years (range, 37–80 years), 57.6% had performance status 0 and
54.6% had adenocarcinoma histology. The median number of pre-
vious regimens was 2 (range, 1–6). The maximum tolerated dose of
pemetrexed in combination with cetuximab was determined to be
750 mg/m2. The median TTP was 14.6 weeks. The median survival
time was 42 weeks and 1-year survival was 38.5%.
Conclusion: The combination of pemetrexed at 750 mg/m2 every 21
days with weekly cetuximab at 250 mg/m2 was feasible; however, in
this unselected patient population, the combination regimen does not
seem to improve TTP compared with historical controls of either
single agent.
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The treatment of patients with metastatic non-small celllung cancer (NSCLC) remains challenging. Although a
majority of patients with a good performance status (PS)
achieve temporary disease control with initial therapy, cancer
progression is universal. The success of achieving subsequent
disease control is diminished possibly because chemothera-
py-resistant clones become a more dominant cell population
within the tumor. There are only three agents approved by the
Food and Drug Administration for treating patients beyond
first-line therapy. Pemetrexed,1 docetaxel,2 and erlotinib3 are
each approved in the second-line setting, and erlotinib is also
approved in the third-line setting. Each has modest single-
agent activity (response rate, 10%) and results in an im-
provement in median survival of only 2 to 3 months.
The initial phase I and II studies of pemetrexed were
conducted without vitamin B12 and folate supplementation
and identified the maximum tolerated dose (MTD) to be 500 to
600 mg/m2.4,5 The addition of these vitamins results in signifi-
cantly reduced toxicity without apparent loss of efficacy.6,7
Subsequent trials have identified the MTD of pemetrexed when
given with vitamin supplementations to be 900 to 1000 mg/m2.8,9
At the time of this study, the efficacy of escalated doses of
pemetrexed against NSCLC was unknown.
Cetuximab (C225, Erbitux, BMS) is a chimeric monoclo-
nal antibody that targets the epidermal growth factor receptor
(EGFR),10 which is overexpressed in most patients with
NSCLC.11 Through blocking ligand binding to EGFR, cetux-
imab leads to a decrease in receptor dimerization, autophosphor-
ylation, and activation of signaling pathways.12 In a phase II
trial, evaluating cetuximab in patients with relapsed NSCLC, the
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response rate was 4.5%, stable disease was seen in 30.3% of
patients, and median survival time (MST) was 8.9 months.13
Therefore, we conducted this trial to evaluate the feasibil-
ity of combining higher doses of pemetrexed with cetuximab in
patients with recurrent NSCLC. Once a MTD was identified,
additional patients were enrolled to estimate whether the com-
bination may be superior to the activity of each agent individu-
ally in this therapeutically challenging patient population.
PATIENTS AND METHODS
Eligibility criteria included age more than or equal to
18 years, histologic or cytologic diagnosis of NSCLC (any
histology), previous therapy with at least one platinum con-
taining regimen for either locally advanced or metastatic
disease, Eastern Cooperative Oncology Group PS of 0 to 1,
and measurable disease by RECIST group response criteria.
Adequate hematologic (absolute neutrophil count 1500/
mm3, platelets 100,000/mm3), renal (creatinine clearance
45 ml/min), and liver function at baseline (bilirubin 
upper limit of normal, aspartate transaminase 1.5  upper
limit of normal, alkaline phosphatase 5  upper limit of
normal) were required. Patients with previous brain metasta-
ses were allowed if they had been adequately treated for their
brain metastases and were asymptomatic and off steroids.
Patients must not have received radiation or chemotherapy
within 3 weeks of registration or any investigational drugs
within 30 days of registration. Patients were excluded if they
had serious concomitant systemic disorders or history of
uncontrolled cardiac disease. They were also excluded if they
had received previous therapy with pemetrexed or cetuximab,
were pregnant, or breast-feeding. All patients provided writ-
ten informed consent before enrolling on the study.
Pretreatment evaluation included history and physical
examination, assessment of Eastern Cooperative Oncology
Group PS, complete blood count with differential, and chem-
istry panel obtained within 14 days of registration, and a
computed tomography scan of chest and upper abdomen
obtained within 28 days of registration. Brain and bone
imaging was obtained only if clinically indicated. Women of
childbearing age must have a negative pregnancy test within
7 days of registration. Laboratory tests were repeated weekly
(days 1, 8, and 15), and disease evaluation by computed
tomography was repeated every other cycle.
Treatment Plan
All patients received a loading dose of cetuximab of
400 mg/m2 intravenously (IV) over 120 minutes on day 7
followed by weekly doses of 250 mg/m2 IV over 60 minutes.
Patients were premedicated with 50 mg IV of diphenhydra-
mine hydrochloride (or an equivalent antihistamine) 30 to 60
minutes before the first dose of cetuximab. All patients received
folic acid, vitamin B12, and dexamethasone per the label of
pemetrexed. Pemetrexed was given starting day 1 of each 21 day
cycle following cetuximab. Patients were treated with up to six
cycles of pemetrexed and cetuximab and in the absence of
disease progression were allowed to remain on weekly cetux-
imab until the time of progressive disease or toxicity.
Up to four dose levels of pemetrexed were to be
evaluated (500, 600, 750, and 900 mg/m2) in a standard 3 
3 design. Three patients were initially enrolled at dose level
1. If no patients experienced dose limiting toxicities (DLTs),
three patients were enrolled at the next dose level. If one of
three patients at any dose level experienced a DLT, three
additional patients were enrolled at that dose level. If only
one of six patients experienced a DLT, dose escalation was
permitted. If two or more patients at any dose level experi-
enced a DLT, then the previous dose was considered the
MTD. The DLTs for the phase I trial would include any
toxicity that required dose modifications or delays based
on  grade 3 toxicities including hematologic toxicity, mu-
cositis, diarrhea, and rash.
Once the MTD of pemetrexed in combination with
cetuximab was determined, patients were subsequently en-
tered onto the phase II portion of the trial and treated at the
recommended dose.
Statistical Analysis
The primary objective of the phase I portion was to
determine the MTD of the combination of pemetrexed and
cetuximab in this patient population. Secondary objectives
were to characterize the DLTs.
The primary end point of the phase II portion was to
estimate the time to disease progression (TTP) of the com-
bination. The secondary end points included estimation of
clinical benefit rate (complete response plus partial response
plus stable disease lasting at least 90 days), MST and to
further characterize the toxicity profile of this regimen.
All phase I patients that were treated at the MTD were
rolled over to the phase II portion when determining the
efficacy analysis. The median TTP using historical controls is
approximately 12 weeks. With a total number of 22 patients,
91% power, and   5%, this design could detect a doubling
of the median TTP to 24 weeks. Anticipating a 10% lost-to-
follow-up rate, the sample size for the phase II portion would
be approximately 25 patients.
RESULTS
Between May 15, 2005 and May 22, 2006, 36 patients
were enrolled onto the study (phase I: n  13, phase II: n 
23). Baseline characteristics of phase I and phase II patients
are summarized in Table 1.
In the phase I portion of the study, the DLTs identified
included acneform rash, alanine aminotransferase elevation, fe-
brile neutropenia, dizziness, and dyspnea. The MTD for pem-
etrexed was determined to be 750 mg/m2 IV every 21 days when
combined with cetuximab at 250 mg/m2 administered IV on a
weekly basis.
Treatment Administered
The median number of cycles administered on the
phase I portion was 3 (range, 1–6). Nine patients tolerated
treatment without dose modifications or delays of either
pemetrexed or cetuximab. Three patients required dose mod-
ifications or delays of either pemetrexed or cetuximab (two of
pemetrexed and one of cetuximab) because of toxicity.
Median number of cycles administered on the phase II
portion was 4 (range, 1–34). Ten and 15 patients tolerated
treatment with pemetrexed and cetuximab, respectively, with-
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out dose modifications or delays. A total of nine patients
required dose modifications (five of pemetrexed and four of
cetuximab) because of toxicity. Three patients required dose
modifications of pemetrexed because of intercurrent illness.
Three patients received maintenance cetuximab for 8,
9, and 34 cycles, respectively, after 6 cycles of the combina-
tion as allowed per study schema.
Efficacy
Efficacy data is based on 27 patients including six
treated at the MTD of the phase I portion of the trial, and 21
patients treated on the phase II portion (two additional pa-
tients enrolled on the phase II portion were not considered in
this evaluation as they withdrew consent before receiving any
treatment). The median TTP was 14.6 weeks and 6 month
TTP rate was 38.7% (Figure 1). The MST was 42 weeks, and
1-year survival rate was 38.5% (Figure 2). One complete
response was observed in addition to two partial responses for
an overall response rate of 11.1%. Fifteen additional patients
achieved stable disease (57.7%). The clinical benefit rate
(defined as complete responses, partial responses and stable
disease lasting 90 days) was 69.2%.
Safety/Toxicity
Phase I and II toxicities occurring in 10% or more of
patients are outlined in Table 2, respectively. No anaphylactic
or infusion reactions were reported with either agent. Of note,
hematologic toxicities were minimal. The most common
toxicities were acne-like rash, fatigue, mucositis, and nausea.
DISCUSSION
The current study demonstrated the feasibility of combin-
ing pemetrexed up to 750 mg/m2 IV every 3 weeks with
cetuximb 250 mg/m2 IV weekly in patients with recurrent
NSCLC. Nevertheless, although the combination was generally
well tolerated, efficacy outcomes were disappointing and failed
to demonstrate improved TTP over historical controls with
each single agent. To our knowledge, only one other study
has evaluated the combination of cetuximab with chemother-
TABLE 1. Baseline Characteristics for Phase I/II Patients
Characteristics
Phase I Patients
(n  12)
Phase II Patients
(n  21)
Age, yr
Median 63 66
Range 37–68 46–80
Sex
Male 7 (58) 13 (62)
Female 5 (42) 8 (38)
ECOG PS
0 8 (67) 11 (52.4)
1 4 (33) 10 (47.6)
Stage of disease
III 0 (0) 2 (9.5)
IV 12 (100) 19 (90.5)
Tumor histology
Adenocarcinoma 6 (50) 12 (57.1)
Squamous cell carcinoma 1 (8) 7 (33.3)
Large cell carcinoma 2 (17) 0 (0)
Non-small cell carcinoma (NOS) 3 (25) 2 (9.5)
Smoking history
Current 2 (17) 4 (19.1)
Former 9 (75) 15 (71.4)
Never 1 (8) 2 (9.5)
Previous treatments
1 Chemotherapy 9 (75) 17 (81)
2 Chemotherapy 2 (17) 3 (14.2)
2 Chemotherapy 1 (8) 1 (4.8)
Previous targeted therapy 3 (25) 3 (14.2)
Previous radiotherapy 4 (33) 10 (47.6)
Median time since prior
regimen, d
133 96
Median time since initial
diagnosis to registration, d
387.5 282
Values in parenthesis are in percent.
ECOG PS, Eastern Cooperative Oncology Group performance status.
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FIGURE 1. Kaplan-Meier curve for median sur-
vival in weeks (n  27).
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apy in patients with previously treated patients with NSCLC.
Kim et al.14 combined cetuximab with docetaxel in 54 pa-
tients with advanced NSCLC who progressed or recurred
within 3 months of first-line chemotherapy. Median TTP was
104 days and median overall survival was 7.5 months. The
modest efficacy outcomes of these trials suggest that the
addition of cetuximab in an unselected patient population in
this setting is unlikely to result in significantly superior
outcomes to single-agent therapy alone.
Because the completion of this trial additional informa-
tion has emerged regarding the use of pemetrexed. Pem-
etrexed is now approved for use only in patients with
nonsquamous histology based on both prospective and retro-
spective analyses from separate trials demonstrating signifi-
cant superiority of pemetrexed in patients with nonsquamous
histology.15–17 Second, two randomized trials have compared
giving a standard dose of pemetrexed at 500 mg/m2 versus a
higher dose (900 or 1000 mg/m2) in the second-line set-
ting.18,19 Neither of these trials demonstrated any therapeutic
advantage to dose escalation of pemetrexed.
Similarly, additional information has been reported on
cetuximab in the treatment of NSCLC. A phase III trial
randomized untreated patients with EGFR detectable NSCLC
to cisplatin and vinorelbine with or without cetuximab.20
Response rates were modestly improved with the addition of
cetuximab and median survival improved 1.2 months (HR,
0.87; p  0.04). Similar benefits were seen in patients with
squamous cell and adenocarcinoma. A smaller phase III trial
compared carboplatin with a taxane (docetaxel or paclitaxel)
with and without cetuximab.21 Response rates were slightly
improved with cetuximab, but there was no difference in
overall survival.
Recently Hirsch et al.22 reported that increased EGFR
gene copy number detected by fluorescence in situ hybrid-
ization analysis may be predictive of improved disease con-
trol rate (81% versus 55%, p  0.02) and median survival
(p  0.04) in patients with NSCLC treated with cetuximab
and chemotherapy. Future studies will be evaluating cetux-
imab-based regimens in an enriched patient population eval-
uating for differential effects on EGFR FISH-positive and
-negative patient populations. In addition, patients with met-
astatic colorectal cancer were more likely to benefit from
cetuximab combined with chemotherapy if their tumors ex-
pressed kirsten rat sarcoma viral oncogene wild type com-
pared with those with mutant type.23 Similar efforts are
underway to evaluate kirsten rat sarcoma viral oncogene as a
molecular marker of cetuximab in NSCLC.
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FIGURE 2. Kaplan-Meier curve for median time
to disease progression (TTP) in weeks (n  27).
TABLE 2. Phase I/II Toxicity
Toxicity
Phase I
(n  12)
Any
Grade (%)
Phase I
(n  12)
Grade
3/4 (%)
Phase II
(n  21)
Any
Grade (%)
Phase II
(n  21)
Grade
3/4 (%)
Acne-like rash 58.3 16.7 57 23.8
ALT elevation 33.3 16.7 0 0
Hematologic
Anemia 0 0 14.3 0
Thrombocytopenia 8.3 0 14.3 0
Neutropenia 8.3 0 4.8 4.8
Febrile neutropenia 8.3 8.3 0 0
Dizziness 8.3 8.3 19 4.8
Dyspnea 25 8.3 33.3 0
Cough 25 0 28.6 0
Fatigue 33.3 0 76 4.8
Anorexia 33.3 0 19 4.8
Mucositis 41.7 0 38 4.8
Nausea 33.3 0 28.6 0
Diarrhea 33.3 0 33.3 9.5
Constipation 16.7 0 23.8 4.8
Fever (no neutropenia) 8.3 0 19 4.8
Headache 50 0 23.8 0
Hypomagnesemia 0 0 19 4.8
Vomiting 16.7 0 23.8 4.8
ALT, alanine aminotransferse.
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In conclusion, our study failed to demonstrate improved
efficacy outcomes with the combination of pemetrexed and
cetuximab in previously treated patients with advanced NSCLC.
Future studies will involve enriched patient populations who are
most likely to benefit from these agents.
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